The general objective of this study was to investigate the prescribing patterns and cost of antiretroviral (ARV) 
INTRODUCTION
HIV/AIDS is already the leading cause of death worldwide (United Nations Children's Fund, 2004:10) (Dorrington, Bradshaw, Johnson & Budlender, 2004:iii) .
Many people infected do not have access to even the basic drugs needed to treat HIV-related infections and other conditions (Wikipedia, 2004) . Projections indicate that, in the absence of antiretroviral treatment, the number of deaths due to AIDS is expected to result in a cumulative total of five to seven million in South Africa by 2010 (Dorrington, Bourne, Bradshaw, Laubscheer & Timaeus, 2001) . The relative high price of many of the antiretroviral (ARV) drugs and diagnostics on the other hand forms one of the main barriers to their availability in developing countries (United Nations Children's Fund, 2004:77) . Weiser, Wolfe, Bangsberg, Thior, Gilbert, Makhema, Kebaabetswe, Dickenson, Mompati, Essex and Marlink (2003:281) found in a study in Botswana that the cost of ARV drug therapy was the most significant barrier to antiretroviral drug therapy adherence (44%), followed by stigma (15%), travel/migration (10%) and side-effects (9%).
Both the public and private sectors are implementing various interventions (Dorrington et al. 2004:2-3) . These interventions are exercising a significant impact on the course of the epidemic. The mother-to-child transmission prevention programme has reduced the number of babies infected and behaviour change, in particular, has seen an increase in condom use and has reduced the number of adults infected. The national antiretroviral treatment programme can be expected to play a particularly important role in the future outcome of the epidemic (Dorrington et al. 2004:5) . Bardi, Maartens, Mandalia, Bekker, Penrod, Platt, Wood and Beck (2006) 
PRIVATE SECTOR INVOLVEMENT IN THE PROVISION OF ARV DRUGS
Since January 2005, all medical schemes had to provide minimum benefits to members who had HIV/AIDS (Erasmus, 2005:1) guidelines applicable in the public sector (Martinson, Radebe, Mntambo & Violar, 2002:238; Stein, McLeod & Achmat, 2002:60; Erasmus, 2005:2) .
Over the last few years, most medical schemes have accepted responsibility for their members with HIV/ AIDS. In addition to legislated prescribed minimum benefits, most medical schemes contract the burden of HIV positive beneficiaries to disease management programmes, which were created to monitor the complex treatment and manage the significant costs associated with HIV/AIDS treatment (Connelly, 2002:8) . Disease management programmes were introduced in order to provide a comprehensive management approach for beneficiaries of contracted medical schemes (Stein et al. 2002:10) .
Disease management programmes potentially cover 89% of all health insurance beneficiaries. Even though beneficiaries of medical schemes have access to the disease management programmes, very few are registered into the programme. Only 18 000 medical scheme members are registered with a disease management programme, representing less than 1% of all beneficiaries. This is low relative to the extent of the epidemic in South Africa as it is estimated that about 5% of all medical scheme members are HIV-positive (Martinson et al. 2002:239) .
There were seven disease management programmes in operation in South Africa during 2002. These included the following: Accesshealth SA, Aid-for-AIDS, Calibre
Clinical Consultants, Discovery Health, Lifesense, MX Health, Newmed and Qualsa (Stein et al. 2002:10) .
The inclusion of antiretroviral therapy into the prescribed minimum benefits for HIV has a limited effect on medical schemes. This is the conclusion of a study done Because HIV is a relatively new infection, many of the drugs developed specifically to treat HIV/AIDS are still under patent protection in some countries and marketed at very high prices (Bellamy, 2001:6) 
DEFINITION OF TERMS
Generic drug items: Generic drug items are pharmaceutical products usually intended to be interchangeable with the innovator drug items, manufactured without a licence from the innovator manufacturer and marketed after the expiry of patent or other exclusivity rights (World Health Organisation, 2003:116) . Generic drug items contain the same active pharmaceutical ingredients, the same quantities thereof, and are in the same pharmaceutical dosage form as the innovator drug items. 
Innovator drug items:

Weighted arithmetic mean:
The weighted arithmetic mean is used when a joint arithmetic mean of different sets of data is computed from the arithmetic means of the individual sets.
AIM OF THE STUDY
The aim of this study was to investigate the prescribing Data were analysed by using the Statistical Analysis System ® , SAS 9.1 (SAS for Windows, 9.1, 2005) . Effect size (d-value) was used as a descriptive statistic (Steyn, 1999:3) . The effect sizes were utilised in determining whether there were practical significant differences between averages. A d-value of 0.8 or higher was assumed to have practical significance. For the purpose of this study the cost-prevalence index was calculated as an indicator of the relative expensiveness of ARV drug items. Serfontein (1989:180) defined cost-prevalence index as follows:
Cost-prevalence index = (%) Prevalence (%) Cost
The cost-prevalence index will be interpreted as follows:
• If cost-prevalence index < 1 then the drug item utilised is relatively inexpensive.
• If cost-prevalence index = 1 then there is an equilibrium between the cost and prevalence of the drug item.
• If cost-prevalence index > 1 then the drug item utilised is relatively expensive.
Data were directly retrieved at the end of each year from the medicine claims database, thus no direct manipulation of the data by the researcher was possible. The datasets were verified by testing for outlying data, as well as by performing random data checks.
For the purpose of this study surgical equipment, nonmedical items (needles, syringes) and mixtures (with unidentifiable active ingredients) were excluded from analysis.
Data for the analysis were obtained from one medicine claims database, thus, limiting external validity, implying that results can only be generalised to the specific database used, as well as to the specific study population. Each prescription record contained a unique number to identify each patient, medical practice, pharmacy or medical scheme. These numbers were randomly allocated by the medical scheme administrator providing the data to ensure confidentiality. Thus no specific patient, medical practice, pharmacy or medical scheme could be identified. Thus confidentiality of information was maintained throughout the study. The database consists of the following information:
• A specific code for the medical scheme (the specific medical scheme could not be identified) • Medical scheme member number Table 2 gives the general prescribing patterns of drug items as well as all ARV drug items for the three study Table 2 ).
RESULTS
General prescribing patterns (prevalence and cost) of antiretroviral drugs
The results in Table 2 
General prescribing patterns of innovator and generic antiretroviral drugs
The results in Table 2 reveal that the total number of (Table 3) . The results in Table 4 Table 2 indicates an increasing trend in the weighted average • The medicine claims database that provided these data.
Prevalence and cost of ARV drug items based on different categories
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